Chronic myelogenous leukemia typically affects people later in life, at an age when they may be at greater risk of medication-related side effects. Aging bodies don’t necessarily process medications as well, and the situation can be complicated by other medical conditions, such as hig
Nature has long been the source of many of the pharmaceuticals used to treat various illnesses, including different types of cancer. An estimated 60% of all cancer drugs originate from natural products, such as trees, shrubs, fruits and vegetables, and marine animals. Perhaps one of t
Chronic myelogenous leukemia is now routinely treated with a tyrosine kinase inhibitor (TKI), a family of drugs that blocks leukemia signalling in the bone marrow and arrests the disease process. Three TKIs are approved for use in people newly diagnosed with chronic-phase CML: Gleevec
Clinical trials of medications generally exclude people with medical conditions other than the condition being studied, so little is known about whether these treatments are safe in a wide range of people. This issue is especially important in CML, because the disease affects older pe
American Society of Hematology 57th Annual Meeting, Orlando FL, December 5-8, 2015 – Brand-name drugs are new therapies (or “me-too” drugs) that are rigorously tested before they are allowed on the market by regulatory bodies, such as the U.S. Food and Drug Administration or Hea
A new goal in treating CML is treatment-free remission (TFR). What this means is that CML is so deeply suppressed with treatment that the person is able to stop the medication altogether and the leukemia doesn’t return. The physical advantages of TFR will be obvious to anyone taking o
It’s not always a simple matter to get access to the medications you need, but a delay in starting treatment for CML can jeopardize the success of therapy. This was shown in a recent study conducted in Bosnia, where people often face considerable red tape before they can start a
Chronic myelogenous leukemia is a hot area of medical research, in part because of the development of the first effective treatment (Gleevec) a decade ago and the insights about the biology of the disease that have resulted from that important discovery.
Many people with CML start treatment with a second-generation medication, such as Sprycel or Tasigna, because they more potently suppress the proliferation of leukemia cells. But how do these two medications compare?